Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma

Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Dr. Ruth Herzog

Media Contact TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Big data analysis powers the fight against Alzheimer’s

New research helps explain the progression of Alzheimer’s disease and predicts its severit. Alzheimer’s disease has always had its puzzles and contradictions. For Pacific Northwest National Laboratory (PNNL) researcher Vladislav…

New potential mechanism for vision loss discovered

Thanks to laboratory produced human mini-retinas, researchers were able to observe complex changes in the retina as they occur in macular degeneration. This enabled them to discover the so-called cell…

Programmable heat transition

Effective thermal management with programmable materials. Energy is scarce – and like all scarce things, it comes at a price. That is why Germany needs to greatly reduce its energy…

Partners & Sponsors